<DOC>
	<DOCNO>NCT01742013</DOCNO>
	<brief_summary>GCJBP Laennec Injection contain variety cytokine derive human placenta , amino acid , peptide , nucleobases , carbohydrate . This product approve improving liver function . Also , prescribe lots disease menopausal disorder , atopic dermatitis , skin care well fatigue long time . Although action mechanism clinical effectiveness still clear , report say strong probability clinical effectiveness chronic fatigue patient . This study aim investigate safety efficacy GCJBP Laennec Inj . ( Human placenta hydrolysate ) chronic fatigue patient randomize controlled tial .</brief_summary>
	<brief_title>Investigator Initiated Clinical Study Explore Efficacy Safety Human Placenta Hydrolysate Chronic Fatigue Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<criteria>Patient diagnose chronic fatigue syndrome idiopathic chronic fatigue Given write informed consent Male female age 20 65 Patient read answer write questionnaire Patient agree visit clinic study drug injection 3 time per week 6 week Patient administrate investigational product 28 day prior screen visit Patient pregnant childbearing potential female patient consent contraception study Patient hypersensitivity provoke study drug others drive animal Patient receive human placenta product 6 month study participation Abnormal liver function Abnormal renal function Back Depression Inventory ( BDI ) II 29 Underlying disease/conditions , investigator 's judgment , unable participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Chronic Fatigue</keyword>
	<keyword>CFS</keyword>
	<keyword>ICF</keyword>
	<keyword>human placenta</keyword>
</DOC>